112 related articles for article (PubMed ID: 2434569)
1. Isolation of decay accelerating factor (DAF) by a two-step procedure and determination of its N-terminal sequence.
Davitz MA; Schlesinger D; Nussenzweig V
J Immunol Methods; 1987 Feb; 97(1):71-6. PubMed ID: 2434569
[TBL] [Abstract][Full Text] [Related]
2. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
Kameyoshi Y; Matsushita M; Okada H
Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
[TBL] [Abstract][Full Text] [Related]
3. Isolation of two forms of decay-accelerating factor (DAF) from human urine.
Nakano Y; Sugita Y; Ishikawa Y; Choi NH; Tobe T; Tomita M
Biochim Biophys Acta; 1991 Jul; 1074(2):326-30. PubMed ID: 1712233
[TBL] [Abstract][Full Text] [Related]
4. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
5. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.
Medof ME; Walter EI; Roberts WL; Haas R; Rosenberry TL
Biochemistry; 1986 Nov; 25(22):6740-7. PubMed ID: 2432921
[TBL] [Abstract][Full Text] [Related]
6. Isolation of decay-accelerating factor (DAF) from rabbit erythrocyte membranes.
Sugita Y; Uzawa M; Tomita M
J Immunol Methods; 1987 Nov; 104(1-2):123-30. PubMed ID: 2445823
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Fujita T; Shinkai Y; Inoue T; Tamura N
Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
[TBL] [Abstract][Full Text] [Related]
9. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kinoshita T; Medof ME; Silber R; Nussenzweig V
J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
[TBL] [Abstract][Full Text] [Related]
10. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).
Holmes CH; Simpson KL; Okada H; Okada N; Wainwright SD; Purcell DF; Houlihan JM
Eur J Immunol; 1992 Jun; 22(6):1579-85. PubMed ID: 1376264
[TBL] [Abstract][Full Text] [Related]
11. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
Kinoshita T; Medof ME; Nussenzweig V
J Immunol; 1986 May; 136(9):3390-5. PubMed ID: 2420889
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
14. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
15. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
[TBL] [Abstract][Full Text] [Related]
16. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
17. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
18. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.
Holmes CH; Simpson KL; Wainwright SD; Tate CG; Houlihan JM; Sawyer IH; Rogers IP; Spring FA; Anstee DJ; Tanner MJ
J Immunol; 1990 Apr; 144(8):3099-105. PubMed ID: 1691227
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
20. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
Schönermark S; Rauterberg EW; Shin ML; Löke S; Roelcke D; Hänsch GM
J Immunol; 1986 Mar; 136(5):1772-6. PubMed ID: 2419413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
